Neuropathologic features of central nervous system hemangioblastoma

키워드

참고문헌 (100)

1. Tse JY, "Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas", Am J Clin Pathol, 107, pp.459~466 (1997)
2. "Central nervous system tumours" (2021)[URL]
3. Yin X, "Incidence, prognostic factors and survival for hemangioblastoma of the central nervous system : analysis based on the Surveillance, Epidemiology, and End Results Database", Front Oncol, 10, pp.570103~ (2020)
4. Ostrom QT, "CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018", Neuro Oncol, 23, pp.iii1~iii105 (2021)
5. Surawicz TS, "Descriptive epidemiology of primary brain and CNS tumors : results from the Central Brain Tumor Registry of the United States, 1990-1994", Neuro Oncol, 1, pp.14~25 (1999)
6. Constans JP, "Posterior fossa hemangioblastomas", Surg Neurol, 25, pp.269~275 (1986)
7. Westwick HJ, "Incidence and prognosis of spinal hemangioblastoma : a Surveillance Epidemiology and End Results study", Neuroepidemiology, 46, pp.14~23 (2016)
8. Nguyen HS, "Intracranial hemangioblastoma : a SEER-based analysis 2004-2013", Oncotarget, 9, pp.28009~28015 (2018)
9. Neumann HP, "Hemangioblastomas of the central nervous system : a 10-year study with special reference to von Hippel-Lindau syndrome", J Neurosurg, 70, pp.24~30 (1989)
10. Conway JE, "Hemangioblastomas of the central nervous system in von Hippel-Lindau syndrome and sporadic disease", Neurosurgery, 48, pp.55~62 (2001)
11. Lonser RR, "von Hippel-Lindau disease", Lancet, 361, pp.2059~2067 (2003)
12. Glasker S, "The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system", J Neurol Neurosurg Psychiatry, 67, pp.758~762 (1999)
13. Lonser RR, "Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease", J Neurosurg, 120, pp.1055~1062 (2014)
14. Doyle LA, "Peripheral hemangioblastoma : clinicopathologic characterization in a series of 22 cases", Am J Surg Pathol, 38, pp.119~127 (2014)
15. Nonaka D, "Extraneural hemangioblastoma : a report of 5 cases", Am J Surg Pathol, 31, pp.1545~1551 (2007)
16. Maher ER, "Clinical features and natural history of von Hippel-Lindau disease", Q J Med, 77, pp.1151~1163 (1990)
17. Chew EY, "Ocular manifestations of von Hippel-Lindau disease : clinical and genetic investigations", Trans Am Ophthalmol Soc, 103, pp.495~511 (2005)
18. Yousef A, "Sporadic and Von-Hippel Lindau disease-associated spinal hemangioblastomas : institutional experience on their similarities and differences", J Neurooncol, 143, pp.547~552 (2019)
19. Maher ER, "von Hippel-Lindau disease : a clinical and scientific review", Eur J Hum Genet, 19, pp.617~623 (2011)
20. Maher ER, "Von Hippel-Lindau disease : a genetic study", J Med Genet, 28, pp.443~447 (1991)
21. Seizinger BR, "Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma", Nature, 332, pp.268~269 (1988)
22. Knudson AG Jr, "Heredity and cancer in man", Prog Med Genet, 9, pp.113~158 (1973)
23. Kim WY, "Role of VHL gene mutation in human cancer", J Clin Oncol, 22, pp.4991~5004 (2004)
24. Pause A, "The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal", Proc Natl Acad Sci U S A, 95, pp.993~998 (1998)
25. Sendoel A, "HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase", Nature, 465, pp.577~583 (2010)
26. Tang N, "pVHL function is essential for endothelial extracellular matrix deposition", Mol Cell Biol, 26, pp.2519~2530 (2006)
27. Jaakkola P, "Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation", Science, 292, pp.468~472 (2001)
28. Ivan M, "HIFalpha targeted for VHL-mediated destruction by proline hydroxylation : implications for O2sensing", Science, 292, pp.464~468 (2001)
29. Yu F, "HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation", Proc Natl Acad Sci U S A, 98, pp.9630~9635 (2001)
30. Semenza GL, "Oxygen sensing, homeostasis, and disease", N Engl J Med, 365, pp.537~547 (2011)
31. Schodel J, "High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq", Blood, 117, pp.e207~e217 (2011)
32. Favier J, "Pheochromocytomas : the(pseudo)-hypoxia hypothesis", Best Pract Res Clin Endocrinol Metab, 24, pp.957~968 (2010)
33. Li M, "Two sides to every story : the HIF-dependent and HIF-independent functions of pVHL", J Cell Mol Med, 15, pp.187~195 (2011)
34. Glasker S, "Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system", J Neurol Neurosurg Psychiatry, 70, pp.644~648 (2001)
35. Lee JY, "Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas", Cancer Res, 58, pp.504~508 (1998)
36. Shankar GM, "Sporadic hemangioblastomas are characterized by cryptic VHL inactivation", Acta Neuropathol Commun, 2, pp.167~ (2014)
37. Takayanagi S, "Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system", Neuro Oncol, 19, pp.1228~1236 (2017)
38. Jagannathan J, "Surgical management of cerebellar hemangioblastomas in patients with von Hippel-Lindau disease", J Neurosurg, 108, pp.210~222 (2008)
39. Glasker S, "Hemangioblastomas and neurogenic polyglobulia", Neurosurgery, 72, pp.930~935 (2013)
40. Krieg M, "Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function", Blood, 92, pp.3388~3393 (1998)
41. Roonprapunt C, "Surgical management of isolated hemangioblastomas of the spinal cord", Neurosurgery, 49, pp.321~327 (2001)
42. Chu BC, "MR findings in spinal hemangioblastoma : correlation with symptoms and with angiographic and surgical findings", AJNR Am J Neuroradiol, 22, pp.206~217 (2001)
43. Wanebo JE, "The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease", J Neurosurg, 98, pp.82~94 (2003)
44. Ene CI, "Spontaneous hemorrhage from central nervous system hemangioblastomas", World Neurosurg, 83, pp.1180~ (2015)
45. Glasker S, "Risk of hemorrhage in hemangioblastomas of the central nervous system", Neurosurgery, 57, pp.71~76 (2005)
46. de San Pedro JR, "Massive hemorrhage in hemangioblastomas literature review", Neurosurg Rev, 33, pp.11~26 (2010)
47. Ho VB, "Radiologic-pathologic correlation : hemangioblastoma", AJNR Am J Neuroradiol, 13, pp.1343~1352 (1992)
48. Parizel PM, "Gd-DTPA-enhanced MR imaging of spinal tumors", AJR Am J Roentgenol, 152, pp.1087~1096 (1989)
49. Ganti SR, "Computed tomography of cerebellar hemangioblastomas", J Comput Assist Tomogr, 6, pp.912~919 (1982)
50. Raz E, "Cyst with a mural nodule tumor of the brain", Cancer Imaging, 12, pp.237~244 (2012)
51. Ganeshan D, "Tumors in von Hippel-Lindau syndrome : from head to toe-comprehensive state-ofthe-art review", Radiographics, 38, pp.849~866 (2018)
52. Commins DL, "Cytologic features of hemangioblastoma : comparison with meningioma, anaplastic astrocytoma and renal cell carcinoma", Acta Cytol, 42, pp.1104~1110 (1998)
53. Wang X, "Primary hemangioblastoma of the kidney with molecular analyses by next generation sequencing : a case report and review of the literature", Diagn Pathol, 17, pp.34~ (2022)
54. 신유주, "Supratentorial Hemangioblastoma with Unusual Features", Journal of Pathology and Translational Medicine, 48(6), pp.462~465 (2014), 대한병리학회[DOI]
55. Hasselblatt M, "Cellular and reticular variants of haemangioblastoma revisited : a clinicopathologic study of 88 cases", Neuropathol Appl Neurobiol, 31, pp.618~622 (2005)
56. Wippold FJ 2nd, "Neuropathology for the neuroradiologist : rosenthal fibers", AJNR Am J Neuroradiol, 27, pp.958~961 (2006)
57. Zec N, "Extramedullary hematopoiesis in cerebellar hemangioblastoma", Neurosurgery, 29, pp.34~37 (1991)
58. Carney EM, "PAX2(-)", PAX8(-), Am J Surg Pathol, pp.2011, 35[DOI]
59. Hoang MP, "Inhibin alpha distinguishes hemangioblastoma from clear cell renal cell carcinoma", Am J Surg Pathol, 27, pp.1152~1156 (2003)
60. Rivera AL, "Useful immunohistochemical markers in differentiating hemangioblastoma versus metastatic renal cell carcinoma", Neuropathology, 30, pp.580~585 (2010)
61. Weinbreck N, "Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear-cell renal cell carcinoma in the brain : utility of aquaporin1combined with cytokeratin AE1", AE3 immunostaining, 2008, pp.32, 1051~1059
62. Polydorides AD, "Metastatic renal cell carcinoma to hemangioblastoma in von Hippel-Lindau disease", Arch Pathol Lab Med, 131, pp.641~645 (2007)
63. Hufnagel TJ, "Immunohistochemistry of capillary hemangioblastoma. Immunoperoxidase-labeled antibody staining resolves the differential diagnosis with metastatic renal cell carcinoma, but does not explain the histogenesis of the capillary hemangioblastoma", Am J Surg Pathol, 13, pp.207~216 (1989)
64. Proescholdt MA, "Expression of hypoxia-inducible carbonic anhydrases in brain tumors", Neuro Oncol, 7, pp.465~475 (2005)
65. Barresi V, "Expression of brachyury in hemangioblastoma : potential use in differential diagnosis", Am J Surg Pathol, 36, pp.1052~1057 (2012)
66. Frank TS, "A detailed immunohistochemical analysis of cerebellar hemangioblastoma : an undifferentiated mesenchymal tumor", Mod Pathol, 2, pp.638~651 (1989)
67. Yang Y, "Hemangioblastoma : clinicopathologic study of 42 cases with emphasis on TFE3 expression", Am J Transl Res, 12, pp.4498~4510 (2020)
68. Wizigmann-Voos S, "Pathology, genetics and cell biology of hemangioblastomas", Histol Histopathol, 11, pp.1049~1061 (1996)
69. Capper D, "Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics : the Heidelberg experience", Acta Neuropathol, 136, pp.181~210 (2018)
70. Venneti S, "MiRNA-9 and MiRNA-200a distinguish hemangioblastomas from metastatic clear cell renal cell carcinomas in the CNS", Brain Pathol, 22, pp.522~529 (2012)
71. Jung SM, "Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma", Mod Pathol, 18, pp.788~794 (2005)
72. Sangoi AR, "The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma : a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10", Adv Anat Pathol, 17, pp.377~393 (2010)
73. Boulagnon-Rombi C, "Immunohistochemical approach to the differential diagnosis of meningiomas and their mimics", J Neuropathol Exp Neurol, 76, pp.289~298 (2017)
74. Menke JR, "Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen", Acta Neuropathol, 130, pp.441~443 (2015)
75. Gold JS, "Clinicopathologic correlates of solitary fibrous tumors", Cancer, 94, pp.1057~1068 (2002)
76. Mena H, "Hemangiopericytoma of the central nervous system : a review of 94cases", Hum Pathol, 22, pp.84~91 (1991)
77. Chmielecki J, "Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors", Nat Genet, 45, pp.131~132 (2013)
78. Schweizer L, "Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein", Acta Neuropathol, 125, pp.651~658 (2013)
79. Robinson DR, "Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing", Nat Genet, 45, pp.180~185 (2013)
80. Doyle LA, "Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics", Mod Pathol, 27, pp.390~395 (2014)
81. Yoshida A, "STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors", Am J Surg Pathol, 38, pp.552~559 (2014)
82. Fouladi M, "Clear cell ependymoma : a clinicopathologic and radiographic analysis of 10 patients", Cancer, 98, pp.2232~2244 (2003)
83. Vege KD, "The immunophenotype of ependymomas", Appl Immunohistochem Mol Morphol, 8, pp.25~31 (2000)
84. Tihan T, "Pathologic characteristics of pediatric intracranial pilocytic astrocytomas and their impact on outcome in 3 countries : a multi-institutional study", Am J Surg Pathol, 36, pp.43~55 (2012)
85. Ligon KL, "The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas", J Neuropathol Exp Neurol, 63, pp.499~509 (2004)
86. Zhang J, "Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas", Nat Genet, 45, pp.602~612 (2013)
87. Nakagawa Y, "Immunohistochemical characterization of oligodendrogliomas : an analysis of multiple markers", Acta Neuropathol, 72, pp.15~22 (1986)
88. Schweizer L, "Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity", Acta Neuropathol, 140, pp.893~906 (2020)
89. Ramani B, "The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paraganglioma", Acta Neuropathol, 140, pp.907~917 (2020)
90. Koch CA, "Pheochromocytoma in von hippel-lindau disease : distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2", Endocr Pathol, 13, pp.17~27 (2002)
91. Koga Y, "Intracranial, intraparenchymal capillary hemangioma : case report", NMC Case Rep J, 7, pp.43~46 (2020)
92. Fish C, "High mitotic activity in a capillary hemangioma of the cauda equina : case report and review of the literature", Clin Neuropathol, 39, pp.135~138 (2020)
93. Kasukurthi R, "Intramedullary capillary hemangioma of the thoracic spine : case report and review of the literature", Rare Tumors, 1, pp.e10~ (2009)
94. Dornbos D 3rd, "Review of the Neurological Implications of von Hippel-Lindau Disease", JAMA Neurol, 75, pp.620~627 (2018)
95. Kano H, "Stereotactic radiosurgery for intracranial hemangioblastomas : a retrospective international outcome study", J Neurosurg, 122, pp.1469~1478 (2015)
96. Huang Y, "Assessment of care pattern and outcome in hemangioblastoma", Sci Rep, 8, pp.11144~ (2018)
97. Asthagiri AR, "Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease", Neuro Oncol, 12, pp.80~86 (2010)
98. Ammerman JM, "Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease : implications for treatment", J Neurosurg, 105, pp.248~255 (2006)
99. Miyagami M, "Clinicopathological study of vascular endothelial growth factor(VEGF), p53, and proliferative potential in familial von Hippel-Lindau disease and sporadic hemangioblastomas", Brain Tumor Pathol, 17, pp.111~120 (2000)
100. Binderup ML, "Survival and causes of death in patients with von Hippel-Lindau disease", J Med Genet, 54, pp.11~18 (2017)

관련 논문AI추천